Manufacturers file Marketing Authorisation Application in EU for ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

The application for this CAR-T cell therapy is supported by results from the Phase Ib/II CARTITUDE-1 study, from which preliminary results suggest a 97% and 67% response and stringent complete response rates respectively.

Source:

PharmaTimes